Congratulations to the Winners of IsoPlexis’ Single-Cell Proteomics Grant Challenge!
We were excited to receive so many innovative abstract submissions for our grant challenge. This Single-Cell Proteomics Grant Challenge invited researchers to submit project proposals demonstrating how they would use IsoPlexis’ functional proteomics platform to accelerate the development of vaccines and therapeutics. The four winners, below, were chosen to receive 12 free IsoCode or CodePlex chips each, advanced analysis support, and experimental design consultation to complete their proposed experiment. Thank you to all the researchers that sent in proposed projects!
The winners are:
- Jing Zeng, MD, University of Washington School of Medicine
- Andrea Griesinger, MS, CU Anschutz
- James Mathew, PhD, Northwestern University
- Layne Weatherford, PhD, and McKenzie Crist, Graduate Student, University of Cincinnati
Jing Zeng’s project will use the IsoPlexis platform to analyze the peripheral blood monocyte polyfunctionality of stage III lung cancer patients undergoing chemoradiation to predict which patients will develop pneumonitis, a dose-limiting toxicity related to lung cancer treatment. This early predictive biomarker could critically improve lung cancer treatment outcomes.
Andrea Griesinger will use IsoPlexis’ platform to characterize the immune microenvironment of Ependymoma of the posterior fossa (PF EPN), an aggressive pediatric brain tumor to better develop future clinical trials in pediatrics to potentially prevent relapse and improve therapy at relapse.
James Mathew’s lab will use the IsoLight platform to study protective versus inflammatory immune statuses of individuals using SARS-CoV-2 peptides. This experiment will serve as the first step in characterizing the immune profiles of transplant patients and non-transplant patients with and without SARS-CoV-2 and facilitate improved therapeutic management and immunization strategies for immunosuppressed transplant patients.
Layne Weatherford, McKenzie Crist and the Takiar Wise-Draper lab will use IsoPlexis’ CodePlex chips to study the relationship between anti-cancer treatment and COVID-19 infection and severity. This study seeks to improve understanding of the relationship between anti-cancer treatment, plasma inflammatory cytokine levels, and COVID-19 severity to help inform the safest treatments during the current pandemic and with future viral infections.
We congratulate and award these four researchers with free IsoCode or CodePlex chips along with experimental design and analysis support from IsoPlexis to conduct their studies. We are excited to see the insights generated from these experiments help to accelerate curative immune medicines and illuminate novel functional mechanisms to create durable, curative impacts on disease.
To learn more about how IsoPlexis’ systems are advancing precision medicine, you can find a list of publications here.